Document is current
Any future updates will be listed below
-
Authors
Li, Hao
Agrawal, Sumit
Zhu, Ning
Cacciabue, Daniela I.
Rivolta, Marcelo N.
Hartley, Douglas E. H.
Jiang, Dan
Ladak, Hanif M.
O’Donoghue, Gerard M.
Rask‑Andersen, Helge https://orcid.org/0009-0006-5736-0981
- License Information
-
More Information
Article History
Received: 17 May 2024
Accepted: 27 September 2024
First Online: 5 November 2024
Declarations
:
: Prof. Marcelo Rivolta is the Founder Director and Chief Scientific Officer of Rinri Therapeutics. Prof. Douglas Hartley is Rinri Therapeutics Chief Medical Officer. Other authors do not have any competing interest.
: All specimens were obtained as part of the body bequeathal program at Western University, London, Ontario, Canada in accordance with the Anatomy Act of Ontario and Western’s Committee for Cadaveric Use in Research (approval #122611). Human temporal bones for surgical injections were sourced from the tissue bank, University of Lund, Sweden in accordance with the National Board of Health and Welfare Regulation SOSFS 2009:30.
